前瞻性陈述

关于前瞻性陈述的说明



本网站包含有关我们业务的前瞻性陈述。这些前瞻性陈述并没有严格地与历史或目前的事实有关,并且他们可能会伴随着“瞄准”,“预期”,“相信”,“可以”,“估计”,“期待”,“预测”,“预期”“”打算“,”可以,“”计划“,”潜力“,”可能“,”意志“和其他词语和类似含义的条款。药物开发和商业化涉及高度的风险,并且只有少数的研发计划导致产品的商业化。早期临床试验的结果可能不会表明完整的结果或从后期或更大的临床试验结果的结果,并不能确保监管批准。您不应依赖于这些陈述或所提出的科学数据。前瞻性陈述受风险和不确定性,可能导致实际结果与此类陈述中反映的实际结果不同,包括:我们对主要产品销售的依赖;由于我们产品市场的重要产品竞争,未能有效竞争;获得和维护我们产品的足够覆盖,定价和报销的困难;存在不利的安全事件,对我们的产品或产品责任索赔的使用限制;未能保护和执行我们的数据,知识产权和其他专有权以及与知识产权索赔和挑战有关的风险和不确定性; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies or may fail to approve or may delay approval of our drug candidates; risks associated with current and potential future healthcare reforms; problems with our manufacturing processes; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development, regulatory approval and commercialization of products and other aspects of our business, which are outside of our control; failure to successfully execute on our growth initiatives; risks relating to management and key personnel changes, including attracting and retaining key personnel; risks relating to investment in and expansion of manufacturing capacity for future clinical and commercial requirements; failure to comply with legal and regulatory requirements; fluctuations in our effective tax rate; the risks of doing business internationally, including currency exchange rate fluctuations; risks related to commercialization of biosimilars; risks related to investment in properties; the market, interest and credit risks associated with our portfolio of marketable securities; risks relating to stock repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; environmental risks; risks relating to the sale and distribution by third parties of counterfeit versions of our products; risks relating to the use of social media for our business; change in control provisions in certain of our collaboration agreements; risks relating to the spin-off of our hemophilia business, including risks of operational difficulties and exposure to claims and liabilities; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These reports are available atwww.sec.gov.或者在781-464-2442致电我们的投资者关系部门。前瞻性陈述仅截至本网站发布的日期(除非指出较早日期),我们不承担公开更新任何前瞻性陈述的义务,无论是新信息,未来事件或其他事项。